What a Clinical Trial Actually Tells You About Your Skincare

The skincare industry uses the word "clinically proven" more freely than almost any other consumer category. It appears on packaging, in advertisements, across social media. It sounds reassuring. It is also, in the majority of cases, meaningless.

There is no regulatory threshold in Australia for what constitutes "clinically proven." A brand can commission a self-assessment survey of 30 participants, ask them whether their skin "felt smoother," and print the results on a label. That is not clinical evidence. It is marketing with a lab coat.

Understanding the difference matters. When you invest in a skincare protocol, you are making decisions about your skin's long-term function. Those decisions deserve to be informed by evidence that has been tested, scrutinised, and held to the same standards applied in medicine.

What Makes a Clinical Trial Credible

Not all studies are equal. The hierarchy of clinical evidence is well established in medicine, and the same framework applies when evaluating skincare ingredients.

At the bottom sit testimonials and brand-funded surveys with self-reported outcomes. These tell you what participants felt, not what objectively changed. Above those are open-label studies, where both the researchers and participants know which treatment is being applied. Useful, but vulnerable to bias.

The standard for credible evidence is the randomised, controlled trial, or RCT. In this design, participants are randomly assigned to either the treatment group or a control group. Neither the participants nor the assessors know who received which treatment. This is called double-blinding, and it exists specifically to remove the influence of expectation from the results.

When the results of an RCT are then submitted to a peer-reviewed journal, independent scientists evaluate the methodology before publication. They look for flaws in the study design, statistical errors, and unsupported conclusions. Only work that survives this review reaches publication.

Dr Alison Jamieson, Cosmetic Physician, applies this evidence hierarchy when selecting ingredients for Aliangé formulations. An ingredient supported by a well-designed RCT published in a respected journal carries fundamentally different weight to one backed by a brand-commissioned consumer panel.

A Case Study: The Dhaliwal Trial

Consider the question at the centre of modern night cream formulation: can a botanical ingredient match retinol's efficacy with fewer side effects?

In 2019, a team at UC Davis published the answer in the British Journal of Dermatology. The study was randomised, double-blind, and conducted over 12 weeks with 44 patients. One group applied bakuchiol. The other applied retinol. Both were assessed using standardised photographic grading, not self-assessment questionnaires.

This design matters. The double-blind structure meant neither the patients nor the clinicians evaluating outcomes knew which product each participant was using. The peer review process at the British Journal of Dermatology, one of the most respected publications in its field, meant the methodology and statistical analysis were examined by independent experts before the results were made public.

The findings: bakuchiol and retinol produced comparable results for wrinkle reduction. For pigmentation improvement, bakuchiol performed slightly better. And on tolerability, the difference was significant. The retinol group experienced more scaling and stinging at every assessment point. The bakuchiol group did not.

Why the Trial Design Matters More Than the Results

Those results are important, but the trial design is what gives them weight. Here is what to look for when you encounter skincare claims backed by "studies."

Sample source. Were the participants independent volunteers or employees of the sponsoring company? The Dhaliwal trial recruited patients through a university dermatology clinic.

Assessment method. Were outcomes measured by calibrated instruments or standardised clinical photography, or by participants filling out a survey? Self-assessment introduces expectation bias. The Dhaliwal trial used blinded photographic grading.

Control group. Was the ingredient compared against a placebo, an active comparator, or nothing at all? Bakuchiol was tested head-to-head against retinol, the established standard. That is a higher bar than testing against an inert cream.

Publication venue. Was the study published in a peer-reviewed journal, or does it exist only in marketing materials? There is a significant difference between data that has been challenged by independent reviewers and data that has only been presented by the company selling the product.

Duration. Skin biology operates on cycles measured in weeks. Meaningful clinical outcomes for wrinkle reduction and pigmentation require a minimum of eight to twelve weeks. Shorter studies may capture initial tolerability data but cannot demonstrate sustained efficacy.

How This Informs Formulation

When Dr Jamieson formulated the Ultimate A Night Cream, the Dhaliwal trial was not the only evidence considered. But it was the only head-to-head RCT comparing bakuchiol and retinol. That distinction is important. It meant the decision to include both ingredients was grounded in the highest available standard of evidence, not speculation or trend.

The formulation logic follows directly from what the trial demonstrated. Retinol remains the most evidence-supported topical active for cell turnover and collagen stimulation. Bakuchiol achieves comparable outcomes through a different biological pathway, without the tolerability issues that cause most people to abandon retinol within the first month. Using both in a precise ratio addresses both efficacy and compliance, the two factors that determine whether a skincare protocol delivers results over time.

This is the distinction between a product built on evidence and one built on claims. Evidence-based formulation starts with the clinical literature and works backward to the ingredient list. Claims-based formulation starts with a trending ingredient and works backward to find a study that sounds supportive.

Reading the Label Differently

The next time you see "clinically proven" on skincare packaging, ask three questions. Was it a randomised, controlled trial? Was it published in a peer-reviewed journal? And was the ingredient tested against an active comparator, not just a placebo?

Most products cannot answer yes to any of those. The Aliangé PM Protocol is built on ingredients that can.

That is not a marketing position. It is a formulation standard. And it is the reason Dr Alison Jamieson, MBBS, FRACGP, Dip Derm, reviews every clinical claim before it reaches you, including the ones in this article.

Dr Alison Jamieson is a Cosmetic Physician with over 40 years of clinical experience treating Australian skin. She formulates the Aliangé range from her practice on Queensland's Sunshine Coast.

Concerned about signs of ageing? Take our 60-second skin quiz to find the protocol matched to your skin.